Table 2.
Univariable Cox regression analyses for overall graft loss according to recipient etiology of liver disease (HCV negative versus HCV positive).
| HCV positive | HCV negative | ||||||
|---|---|---|---|---|---|---|---|
| HR | (95% CI) | P | HR | (95% CI) | P | ||
| RECIPIENT | Age (years) | 0.988 | 0.951-1.026 | 0.517 | 0.998 | 0.973-1.024 | 0.892 |
| Gender (female vs male) | 1.794 | 0.954-3.376 | 0.070 | 1.052 | 0.518-2.135 | 0.888 | |
| MELD score | 0.993 | 0.928-1.063 | 0.845 | 1.050 | 0.993-1.110 | 0.089 | |
| BMI (kg/m2) | 1.065 | 0.967-1.173 | 0.204 | 1.001 | 0.929-1.079 | 0.979 | |
| HCC (yes vs no) | 1.139 | 0.616-2.103 | 0.678 | 1.338 | 0.734-2.439 | 0.342 | |
|
| |||||||
| DONOR | Age (years) | 1.009 | 0.993-1.026 | 0.284 | 1.014 | 0.996-1.032 | 0.119 |
| Gender (female vs male) | 0.983 | 0.530-1.821 | 0.955 | 1.326 | 0.729-2.413 | 0.355 | |
| BMI (kg/m2) | 1.034 | 0.919-1.162 | 0.580 | 0.954 | 0.869-1.046 | 0.314 | |
| Cause of death (non trauma vs trauma) |
1.014 | 0.544-1.891 | 0.965 | 0.867 | 0.456-1.650 | 0.663 | |
| ALT (IU/L) | 1.000 | 0.995-1.005 | 0.948 | 0.998 | 0.992-1.004 | 0.590 | |
| AST (IU/L) | 0.996 | 0.990-1.002 | 0.148 | 0.999 | 0.993-1.005 | 0.797 | |
| Sodium (mEq/L) | 1.008 | 0.979-1.038 | 0.594 | 0.995 | 0.964-1.027 | 0.742 | |
| Hemoglobin (gr/dL) | 0.993 | 0.868-1.137 | 0.923 | 1.049 | 0.916-1.201 | 0.491 | |
| PaO2 (mmHg) | 1.000 | 0.996-1.004 | 0.872 | 0.999 | 0.995-1.002 | 0.557 | |
| Anti-HBc status (pos vs neg) | 1.424 | 0.344-5.902 | 0.626 | 3.190 | 1.565-6.501 | 0.001 | |
| Norepinephrine (yes vs no) | 1.512 | 0.813-2.811 | 0.191 | 0.588 | 0.315-1.0.97 | 0.095 | |
| ICU stay (days) | 1.121 | 1.022-1.229 | 0.015 | 0.555 | 0.954-1.091 | 0.555 | |
|
| |||||||
| GRAFT | Sd-MaS categorical, n (%): | ||||||
| 0% | |||||||
| 1-15% | 0.939 | 0.453-1.948 | 0.866 | 1.284 | 0.622-2.647 | 0.499 | |
| >15% | 0.581 | 0.239-1.415 | 0.232 | 3.146 | 1.525-6.489 | 0.002 | |
| Sd-MaS, continuous variable (% of hepatocytes) |
0.983 | 0.958-1.010 | 0.212 | 1.036 | 1.018-1.055 | <0.001 | |
| Ld-MaS categorical, n (%): | |||||||
| 0% (reference) | |||||||
| 1-15% | 0.841 | 0.445-1.586 | 0.592 | 0.694 | 0.360-1.337 | 0.275 | |
| >15% | 0.650 | 0.194-2.177 | 0.484 | 1.430 | 0.654-3.129 | 0.371 | |
| Ld-MaS, continuous variable (% of hepatocytes) |
0.983 | 0.944-1.024 | 0.406 | 1.016 | 0.992-1.040 | 0.193 | |
| Cold ischemia time (minutes) | 1.007 | 1.003-1.010 | <0.001 | 1.001 | 0.998-1.005 | 0.364 | |
| Warm ischemia time (minutes) | 1.015 | 1.003-1.027 | 0.017 | 0.997 | 0.982-1.012 | 0.718 | |
| IRI score, categorical§ (severe vs mild/moderate) |
2.932 | 1.399-6.145 | 0.004 | 0.961 | 0.365-2.527 | 0.935 | |
| IPGF (yes vs no) | 3.340 | 1.694-6.584 | <0.001 | 2.152 | 1.100-4.212 | 0.025 | |
| EAD (yes vs no) | 1.839 | 1.004-3.371 | 0.049 | 2.346 | 1.252-4.396 | 0.008 | |
| Transplant year | 0.954 | 0.854-1.067 | 0.411 | 0.900 | 0.816-0.993 | 0.036 | |
MELD, model for end-stage liver disease score; HCC, hepatocellular carcinoma; BMI, body mass index; PaO2, partial pressure of oxygen in arterial blood; ICU, intensive care unit; Sd-MaS, small droplet macrovesicular steatosis; Ld-MaS, large droplet macrovesicular steatosis; IRI, histological ischemia/reperfusion injury; IPGF, initial poor graft function; EAD, early allograft dysfunction.
§Available in only 55 and 79 recipients with HCV positive and negative liver disease, respectively.